Real-World Study of a Calcium Sodium Phosphosilicate Anti-Sensitivity Toothpaste for Dentin Hypersensitivity Relief
Condition(s) studied
Investigational drug(s) / intervention(s)
Calcium sodium phosphosilicate (CSPS) Toothpaste: A toothpaste containing 5% weight/weight (w/w) calcium sodium phosphosilicate.
Study summary
The aim of this study is to evaluate the impact of a commercially available desensitizing dentifrice containing 5 percent (%) Calcium sodium phosphosilicate (CSPS) on oral health related quality of life (OHrQoL) in a DH (Dentin Hypersensitivity) population in a real-world setting.
Eligibility
Primary outcome measure(s)
- Change From Baseline in DHEQ Total Score at Week 24 — Baseline and Week 24
The DHEQ is used to measure how DH affects participants quality of life. Section 2 has 34 questions in grouped into 5 domains (Restrictions, Adaptation, Social Impact, Emotional Impact, and Identity). Participants scored each question using a 7-point scale ranging from 1 to 7, where 1= strongly disagree, 2=disagree, 3=disagree a little, 4=neither agree nor disagree, 5=agree a little, 6=agree, and 7=strongly agree. The total score will be derived from the sum of scores across all domains and it ranges from 34 to 238. A lower score indicates a better quality of life regarding DH. Change from Baseline will be calculated by subtracting the Baseline score from the score at Week 24.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Citruslabs (Virtual Site) | Las Vegas | Nevada |
More HALEON trials in the USA
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07300540 on ClinicalTrials.gov ↗ ← All trials in the USA